View in EDS

Pazopanib and Fosbretabulin in recurrent ovarian cancer (PAZOFOS): A multi-centre, phase 1b and open-label, randomised phase 2 trial.

Saved in:
Bibliographic Details
Title: Pazopanib and Fosbretabulin in recurrent ovarian cancer (PAZOFOS): A multi-centre, phase 1b and open-label, randomised phase 2 trial.
Authors: Morgan RD; Christie NHS Foundation Trust, Manchester, UK; Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK., Banerjee S; The Royal Marsden NHS Foundation Trust, London, UK., Hall M; Mount Vernon Cancer Centre, Northwood, Middlesex, UK., Clamp AR; Christie NHS Foundation Trust, Manchester, UK; Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK., Zhou C; Clinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, Manchester, UK., Hasan J; Christie NHS Foundation Trust, Manchester, UK., Orbegoso C; The Royal Marsden NHS Foundation Trust, London, UK., Taylor S; Clinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, Manchester, UK., Tugwood J; Clinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, Manchester, UK., Lyon AR; Royal Brompton and Harefield NHS Foundation Trust, London, UK; Faculty of Medicine, National Heart & Lung Institute, Imperial College London, London, UK., Dive C; Clinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, Manchester, UK., Rustin GJS; Mount Vernon Cancer Centre, Northwood, Middlesex, UK., Jayson GC; Christie NHS Foundation Trust, Manchester, UK; Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK. Electronic address: Gordon.Jayson@christie.nhs.uk.
Source: Gynecologic oncology [Gynecol Oncol] 2020 Mar; Vol. 156 (3), pp. 545-551. Date of Electronic Publication: 2020 Jan 10.
Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Academic Press Country of Publication: United States NLM ID: 0365304 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1095-6859 (Electronic) Linking ISSN: 00908258 NLM ISO Abbreviation: Gynecol Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 31932108
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Pazopanib and Fosbretabulin in recurrent ovarian cancer (PAZOFOS): A multi-centre, phase 1b and open-label, randomised phase 2 trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Morgan+RD%22">Morgan RD</searchLink>; Christie NHS Foundation Trust, Manchester, UK; Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.<br /><searchLink fieldCode="AU" term="%22Banerjee+S%22">Banerjee S</searchLink>; The Royal Marsden NHS Foundation Trust, London, UK.<br /><searchLink fieldCode="AU" term="%22Hall+M%22">Hall M</searchLink>; Mount Vernon Cancer Centre, Northwood, Middlesex, UK.<br /><searchLink fieldCode="AU" term="%22Clamp+AR%22">Clamp AR</searchLink>; Christie NHS Foundation Trust, Manchester, UK; Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.<br /><searchLink fieldCode="AU" term="%22Zhou+C%22">Zhou C</searchLink>; Clinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, Manchester, UK.<br /><searchLink fieldCode="AU" term="%22Hasan+J%22">Hasan J</searchLink>; Christie NHS Foundation Trust, Manchester, UK.<br /><searchLink fieldCode="AU" term="%22Orbegoso+C%22">Orbegoso C</searchLink>; The Royal Marsden NHS Foundation Trust, London, UK.<br /><searchLink fieldCode="AU" term="%22Taylor+S%22">Taylor S</searchLink>; Clinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, Manchester, UK.<br /><searchLink fieldCode="AU" term="%22Tugwood+J%22">Tugwood J</searchLink>; Clinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, Manchester, UK.<br /><searchLink fieldCode="AU" term="%22Lyon+AR%22">Lyon AR</searchLink>; Royal Brompton and Harefield NHS Foundation Trust, London, UK; Faculty of Medicine, National Heart & Lung Institute, Imperial College London, London, UK.<br /><searchLink fieldCode="AU" term="%22Dive+C%22">Dive C</searchLink>; Clinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, Manchester, UK.<br /><searchLink fieldCode="AU" term="%22Rustin+GJS%22">Rustin GJS</searchLink>; Mount Vernon Cancer Centre, Northwood, Middlesex, UK.<br /><searchLink fieldCode="AU" term="%22Jayson+GC%22">Jayson GC</searchLink>; Christie NHS Foundation Trust, Manchester, UK; Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK. Electronic address: Gordon.Jayson@christie.nhs.uk.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%220365304%22">Gynecologic oncology</searchLink> [Gynecol Oncol] 2020 Mar; Vol. 156 (3), pp. 545-551. <i>Date of Electronic Publication: </i>2020 Jan 10.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase I; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Academic+Press%22">Academic Press </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>0365304 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1095-6859 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2200908258%22">00908258 </searchLink><i>NLM ISO Abbreviation: </i>Gynecol Oncol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=31932108
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.ygyno.2020.01.005
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 545
    Titles:
      – TitleFull: Pazopanib and Fosbretabulin in recurrent ovarian cancer (PAZOFOS): A multi-centre, phase 1b and open-label, randomised phase 2 trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Morgan RD
      – PersonEntity:
          Name:
            NameFull: Banerjee S
      – PersonEntity:
          Name:
            NameFull: Hall M
      – PersonEntity:
          Name:
            NameFull: Clamp AR
      – PersonEntity:
          Name:
            NameFull: Zhou C
      – PersonEntity:
          Name:
            NameFull: Hasan J
      – PersonEntity:
          Name:
            NameFull: Orbegoso C
      – PersonEntity:
          Name:
            NameFull: Taylor S
      – PersonEntity:
          Name:
            NameFull: Tugwood J
      – PersonEntity:
          Name:
            NameFull: Lyon AR
      – PersonEntity:
          Name:
            NameFull: Dive C
      – PersonEntity:
          Name:
            NameFull: Rustin GJS
      – PersonEntity:
          Name:
            NameFull: Jayson GC
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 03
              Text: 2020 Mar
              Type: published
              Y: 2020
          Identifiers:
            – Type: issn-electronic
              Value: 1095-6859
          Numbering:
            – Type: volume
              Value: 156
            – Type: issue
              Value: 3
          Titles:
            – TitleFull: Gynecologic oncology
              Type: main
ResultId 1